Key facts
- This page summarizes Scott M. Coiante's Form 4 filing for AGILE THERAPEUTICS INC.
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 26 Aug 2024, 17:42.
Scott M. Coiante - 26 Aug 2024 Form 4 Insider Report for AGILE THERAPEUTICS INC
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 26 Aug 2024
- Net transaction value
- -$30,522
- SEC form
- 4
- Accepted by SEC
- 26 Aug 2024, 17:42:38 UTC
- Prior SEC filing
- 04 Oct 2023
- Next SEC filing
- 02 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Geoffrey P. Gilmore, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Scott M. Coiante filed Form 4 for AGILE THERAPEUTICS INC on 26 Aug 2024.
Change
- Previous filing in this sequence was filed on 04 Oct 2023.
- Current net transaction value: -$30,522.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AGRX
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $22,800
- Shares
- -15,000
- Change %
- -75%
- Price
- $1.52
- Shares after
- 5,080
- Date
- 26 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
AGRX
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $7,722
- Shares
- -5,080
- Change %
- -100%
- Price
- $1.52
- Shares after
- 0
- Date
- 26 Aug 2024
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Scott M. Coiante is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 15,000 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $22,800, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person.
Footnote F2
Upon the consummation of the Merger, pursuant to the Merger Agreement, 5,080 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $7,722, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person.